[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-456174-105":59,"doc-detail-456174-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","eoad-signature-atrophy-predicts-progression-to-dementia-in-patients-with-early-onset-mci-due-to-alzheimers-disease","EOAD-Signature Atrophy Predicts Progression to Dementia in Patients with Early-onset MCI due to Alzheimer’s Disease","","Prognostic risk stratification at the mild cognitive impairment (MCI) stage in early-onset Alzheimer’s disease (EOAD) can support better medical and life planning decisions. The study quantified cortical atrophy magnitude in recently defined EOAD signature regions using MRI in 130 EOAD patients recruited in LEADS. Baseline atrophy, expressed as W-scores, was evaluated as a predictor of time to progression to mild dementia, alone and combined with Clinical Dementia Rating Sum-of-Boxes (CDR-SB).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/eoad-signature-atrophy-predicts-progression-to-dementia-in-patients-with-early-onset-mci-due-to-alzheimers-disease/456174/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/eoad-signature-atrophy-predicts-progression-to-dementia-in-patients-with-early-onset-mci-due-to-alzheimers-disease/456174.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary goal of the poster study?","Question",{"text":112,"@type":113},"To evaluate whether EOAD signature cortical atrophy measured from MRI predicts time to progression to dementia in EOAD patients at the MCI stage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was baseline cortical atrophy measured?",{"text":117,"@type":113},"Baseline cortical atrophy was measured in EOAD signature regions using W-scores, described as Z-scores adjusted for age and sex relative to healthy controls.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results regarding prediction of progression to dementia?",{"text":121,"@type":113},"Greater baseline EOAD signature atrophy predicted a higher risk of progression to dementia and added predictive value beyond CDR-SB, using Cox regression models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},456174,1790790980,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24,"preview_page_count":4},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10. 1002/alz70856_105039  \nBIOMARKERS  \nPOSTER PRESENTATION  \nNEUROIMAGING  \nEOAD-Signature Atrophy Predicts Progression to Dementia in Patients with Early-onset MCI due to Alzheimer’s Disease  \nThiago Paranhos1  Yuta Katsumi2  Michael Brickhouse 1  Ryan Eckbo2  Alexander Zaitsev2  Anna Du2  Ani Eloyan3  Renaud La Joie4   \nKelly N. Nudelman5  Tatiana M. Foroud6  Jeffrey L. Dage5, 6  Maria C. Carrillo7  \nGil D. Rabinovici4  Liana G. Apostolova5, 6, 8  Brad C. Dickerson2   \nAlexandra Touroutoglou2  \n1 Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA  \n2 Frontotemporal Disorders Unit and Massachusetts Alzheimer’s Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA  \n3 Department of Biostatistics, Brown University, Providence, RI, USA  \n4 Department of Neurology, University of California, San Francisco, San Francisco, CA, USA  \n5 Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA  \n6 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA  \n7 Medical & Scientific Relations Division, Alzheimer’s Association, Chicago, IL, USA  \n8 Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA  \nCorrespondence  \nThiago Paranhos, Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Email:](Email: tdpereira@mgh.harvard.edu)[ tdpereira@mgh.harvard.edu](Email: tdpereira@mgh.harvard.edu)  \nAbstract  \nBackground: Prognostic risk stratification for patients at the mild cognitive impairment (MCI) stage of early-onset Alzheimer’s disease (EOAD) would allow professionals and loved ones to make better-informed medical and life planning decisions. While research including our own (Bakkour, Morris, Dickerson, 2009) has demonstrated the prognostic value of MRI-based measures of brain structure in late-onset amnestic AD, its utility for predicting progression to dementia in EOAD remains unclear. Here, we measured the magnitude of cortical atrophy within our recently described EOAD signature regions (Touroutoglou et al. 2023) in patients with EOAD at the MCI stage (N = 130) recruited in LEADS. The main goal of the study was to evaluate the utility of this measure as a predictor of time to subsequent progression to dementia. Our second goal was to examine the independent or synergistic contributions of EOAD signature of atrophy and standard clinical severity measures used in clinical trials.  \nMethod: For each patient, we measured the time between baseline visit and subsequent visit at which progression to mild dementia was documented or last observation. Baseline cortical atrophy was measured as W-scores (i.e., Z-scores adjusted forage and sex relative toa sample of healthy controls)in theEOAD signature. Baseline clinical severity was quantified with the Clinical Dementia Rating Sum-ofBoxes scores (CDR-SB). Simple and multivariable Cox regression models examined the relationship between atrophy in EOAD signature, baseline CDR-SB, and the likelihood of progression to dementia.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e105039.  \n[https://doi.org/10.1002/alz70856_105039](https://doi.org/10.1002/alz70856_105039)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nResult: Greater baseline atrophy in the EOAD signature predicted higher risk of progression to dementia (hazard ratio = 1. 2, 95% CI ","cbCaietrsqLjBj90","https://ap.wps.com/l/cbCaietrsqLjBj90","pdf",93884,"English","# Abstract\n## Background\n## Method\n## Results and Conclusion","[{\"question\":\"What was the primary goal of the poster study?\",\"answer\":\"To evaluate whether EOAD signature cortical atrophy measured from MRI predicts time to progression to dementia in EOAD patients at the MCI stage.\"},{\"question\":\"How was baseline cortical atrophy measured?\",\"answer\":\"Baseline cortical atrophy was measured in EOAD signature regions using W-scores, described as Z-scores adjusted for age and sex relative to healthy controls.\"},{\"question\":\"What were the main results regarding prediction of progression to dementia?\",\"answer\":\"Greater baseline EOAD signature atrophy predicted a higher risk of progression to dementia and added predictive value beyond CDR-SB, using Cox regression models.\"}]","EOAD-Signature Atrophy Predicts Progression to Dementia in Patients with Early-onset MCI due to Alzheimer’s Disease | PDF",1790745277]